Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1963

1.

Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer.

Momtazi-Borojeni AA, Nik ME, Jaafari MR, Banach M, Sahebkar A.

Arch Med Sci. 2019 May;15(3):559-569. doi: 10.5114/aoms.2019.84732. Epub 2019 Apr 30.

2.

Immunization and Moral Hazard: The HPV Vaccine and Uptake of Cancer Screening.

Moghtaderi A, Dor A.

Med Care Res Rev. 2019 May 17:1077558719847887. doi: 10.1177/1077558719847887. [Epub ahead of print]

PMID:
31096862
3.

Vaccine Therapies for Breast Cancer.

Burke EE, Kodumudi K, Ramamoorthi G, Czerniecki BJ.

Surg Oncol Clin N Am. 2019 Jul;28(3):353-367. doi: 10.1016/j.soc.2019.02.004. Epub 2019 Apr 5. Review.

PMID:
31079793
4.

HPV Knowledge and Attitudes Among Medical and Professional Students at a Nevada University: A Focus on Oropharyngeal Cancer and Mandating the Vaccine.

Evans L, Matley E, Oberbillig M, Margetts E, Darrow L.

J Cancer Educ. 2019 May 9. doi: 10.1007/s13187-019-01529-y. [Epub ahead of print]

PMID:
31073868
5.

Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial.

Mittendorf EA, Lu B, Melisko M, Price Hiller J, Bondarenko I, Brunt AM, Sergii G, Petrakova K, Peoples GE.

Clin Cancer Res. 2019 Apr 29. pii: clincanres.2867.2018. doi: 10.1158/1078-0432.CCR-18-2867. [Epub ahead of print]

PMID:
31036542
6.

A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy.

Katsuda M, Miyazawa M, Ojima T, Katanuma A, Hakamada K, Sudo K, Asahara S, Endo I, Ueno M, Hara K, Yamada S, Fujii T, Satoi S, Ioka T, Ohira M, Akahori T, Kitano M, Nagano H, Furukawa M, Adachi T, Yamaue H.

Trials. 2019 Apr 27;20(1):242. doi: 10.1186/s13063-019-3332-5.

7.

Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine.

Belnoue E, Mayol JF, Carboni S, Di Berardino Besson W, Dupuychaffray E, Nelde A, Stevanovic S, Santiago-Raber ML, Walker PR, Derouazi M.

JCI Insight. 2019 Apr 23;5. pii: 127305. doi: 10.1172/jci.insight.127305.

8.

Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.

Snook AE, Baybutt TR, Xiang B, Abraham TS, Flickinger JC Jr, Hyslop T, Zhan T, Kraft WK, Sato T, Waldman SA.

J Immunother Cancer. 2019 Apr 23;7(1):104. doi: 10.1186/s40425-019-0576-2.

9.

Combination of Human Umbilical Vein Endothelial Cell Vaccine and Docetaxel Generates Synergistic Anti-Breast Cancer Effects.

Lu M, Yao Q, Liu H, Zhong W, Gao J, Si C, Zhou L, Zhang S, Xu M.

Cancer Biother Radiopharm. 2019 Apr 22. doi: 10.1089/cbr.2018.2721. [Epub ahead of print]

PMID:
31009240
10.

Ovarian Cancer Stem Cells with High ROR1 Expression Serve as a New Prophylactic Vaccine for Ovarian Cancer.

Wu D, Yu X, Wang J, Hui X, Zhang Y, Cai Y, Ren M, Guo M, Zhao F, Dou J.

J Immunol Res. 2019 Mar 17;2019:9394615. doi: 10.1155/2019/9394615. eCollection 2019.

11.

Could hepatitis B vaccine act as an adjuvant to lower risk and relapses of cancer?

Altinoz MA, Ozpinar A, Ozpinar A, Hacker E, Elmaci İ.

Clin Exp Pharmacol Physiol. 2019 Apr 19. doi: 10.1111/1440-1681.13096. [Epub ahead of print] Review.

PMID:
31002181
12.

MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer.

Zamani P, Navashenaq JG, Nikpoor AR, Hatamipour M, Oskuee RK, Badiee A, Jaafari MR.

J Control Release. 2019 Apr 15;303:223-236. doi: 10.1016/j.jconrel.2019.04.019. [Epub ahead of print]

PMID:
30999007
13.

Heterologous Prime-Boost Enhances the Antitumor Immune Response Elicited by Plant-Virus-Based Cancer Vaccine.

Cai H, Shukla S, Wang C, Masarapu H, Steinmetz NF.

J Am Chem Soc. 2019 Apr 24;141(16):6509-6518. doi: 10.1021/jacs.9b01523. Epub 2019 Apr 16.

PMID:
30995022
14.

Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.

Koske I, Rössler A, Pipperger L, Petersson M, Barnstorf I, Kimpel J, Tripp CH, Stoitzner P, Bánki Z, von Laer D.

Int J Cancer. 2019 Apr 10. doi: 10.1002/ijc.32325. [Epub ahead of print]

PMID:
30972741
15.

Human papillomavirus (HPV) vaccine and HPV-related head and neck cancer: What's next?

De Felice F, Polimeni A, Tombolini V.

Oral Oncol. 2019 Jun;93:125-126. doi: 10.1016/j.oraloncology.2019.04.001. Epub 2019 Apr 5. No abstract available.

PMID:
30956072
16.

Safety Evaluation of Autologous Tissue Vaccine Cancer Immunotherapy in a Canine Model.

Crossley RA, Matz A, Dew T, Kalinauskas A, Faucette N, Poff B, Silbart LK, Suckow MA.

Anticancer Res. 2019 Apr;39(4):1699-1703. doi: 10.21873/anticanres.13275.

PMID:
30952708
17.

Liposomal Fc Domain Conjugated to a Cancer Vaccine Enhances Both Humoral and Cellular Immunity.

Hossain MK, Vartak A, Sucheck SJ, Wall KA.

ACS Omega. 2019 Mar 31;4(3):5204-5208. doi: 10.1021/acsomega.9b00029. Epub 2019 Mar 13.

18.

Magnetic resonance imaging monitoring therapeutic response to dendritic cell vaccine in murine orthotopic pancreatic cancer models.

Pan L, Shang N, Shangguan J, Figini M, Xing W, Wang B, Sun C, Yang J, Zhang Y, Hu S, Ma Q, Wang J, Velichko Y, Yaghmai V, Benson AB 3rd, Zhang Z.

Am J Cancer Res. 2019 Mar 1;9(3):562-573. eCollection 2019.

19.

Transendothelial migration (TEM) of in vitro generated dendritic cell vaccine in cancer immunotherapy.

Ashraf MU, Jeong Y, Roh SE, Bae YS.

Arch Pharm Res. 2019 Apr 1. doi: 10.1007/s12272-019-01145-w. [Epub ahead of print] Review.

PMID:
30937843
20.

Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade.

Mougel A, Terme M, Tanchot C.

Front Immunol. 2019 Mar 14;10:467. doi: 10.3389/fimmu.2019.00467. eCollection 2019. Review.

Supplemental Content

Loading ...
Support Center